vida: extract claims from 2026-04-13-calibrate-glp1-behavioral-interrupted-access-outcomes

- Source: inbox/queue/2026-04-13-calibrate-glp1-behavioral-interrupted-access-outcomes.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

entities/health/calibrate.md

@@ -0,0 +1,45 @@
+# Calibrate
+
+**Type:** Company  
+**Domain:** Health  
+**Status:** Active  
+**Business Model:** Employer-sponsored GLP-1 + behavioral coaching program  
+**Market Position:** Premium-tier weight management program ($200-300+/month depending on employer negotiation)  
+
+## Overview
+
+Calibrate operates an employer-sponsored weight management program combining GLP-1 prescriptions with behavioral coaching across four pillars: food, sleep, exercise, and emotional health. The program targets commercially insured, higher-income populations through employer plans.
+
+## Program Structure
+
+- GLP-1 prescriptions
+- Coaching on food, sleep, exercise, emotional health (four pillars)
+- Regular check-ins and goal tracking
+- Weekly weight tracking (80% member engagement)
+- Coaching session completion (67% member engagement)
+
+## Key Metrics
+
+**Sample size:** n=17,475 members (Endocrine Society 2025 data)
+
+**Primary outcomes (uninterrupted access):**
+- 12-month weight loss: 15.7% average
+- 18-month: 17.3%
+- 24-month: 17.9% (continued loss, not plateau)
+- Waist circumference reduction: avg 6 inches at 12 months
+
+**Interrupted access outcomes:**
+- 12-month weight loss: 13.7% (vs. 17% uninterrupted)
+- 24-month: 14.9% (vs. 20.1% uninterrupted)
+- Delta: ~2.2 percentage points at 12 months; ~5.2 percentage points at 24 months
+
+## Timeline
+
+- **2025-01-01** — Presented interrupted access data at Endocrine Society 2025 showing behavioral coaching creates durability floor: members with treatment interruptions maintained 13.7% weight loss at 12 months vs. standard GLP-1 cessation pattern of ~2/3 weight regain
+
+## Notes
+
+- "Treatment interruptions" criteria not publicly specified
+- Endocrine Society presentation not yet peer-reviewed as standalone paper
+- No control condition (Calibrate members without behavioral coaching) to isolate behavioral program effect
+- Sample entirely employer-sponsored, skewing toward commercially insured, higher-income populations